Total Payments
$4,207
2024 Payments
$221.66
Companies
41
Transactions
230
Medicare Patients
5,161
Medicare Billing
$418,187
Payment Breakdown by Category
Food & Beverage$3,765 (89.5%)
Education$442.73 (10.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,765 | 220 | 89.5% |
| Education | $442.73 | 10 | 10.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme Corporation | $544.82 | 37 | $0 (2020) |
| E.R. Squibb & Sons, L.L.C. | $506.10 | 34 | $0 (2024) |
| Seagen Inc. | $332.81 | 12 | $0 (2023) |
| ABBVIE INC. | $272.48 | 9 | $0 (2024) |
| Daiichi Sankyo Inc. | $232.99 | 13 | $0 (2023) |
| Exelixis Inc. | $215.55 | 10 | $0 (2019) |
| GENZYME CORPORATION | $197.57 | 10 | $0 (2024) |
| Celgene Corporation | $184.71 | 11 | $0 (2023) |
| Astellas Pharma US Inc | $142.42 | 3 | $0 (2023) |
| Alexion Pharmaceuticals, Inc. | $132.87 | 7 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $221.66 | 12 | Eisai Inc. ($54.14) |
| 2023 | $322.24 | 18 | Seagen Inc. ($77.59) |
| 2022 | $363.97 | 11 | Seagen Inc. ($228.57) |
| 2021 | $40.52 | 3 | Janssen Biotech, Inc. ($15.68) |
| 2020 | $236.47 | 13 | Merck Sharp & Dohme Corporation ($47.43) |
| 2019 | $1,062 | 55 | Merck Sharp & Dohme Corporation ($241.72) |
| 2018 | $975.22 | 62 | E.R. Squibb & Sons, L.L.C. ($183.97) |
| 2017 | $985.32 | 56 | Astellas Pharma US Inc ($122.49) |
All Payment Transactions
230 individual payment records from CMS Open Payments — Page 3 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/10/2020 | Celgene Corporation | Revlimid (Drug) | Food and Beverage | Cash or cash equivalent | $18.06 | General |
| Category: Hematology | ||||||
| 02/06/2020 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $15.26 | General |
| Category: ONCOLOGY | ||||||
| 02/03/2020 | Seagen Inc. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $13.84 | General |
| Category: Oncology | ||||||
| 01/28/2020 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $19.53 | General |
| 01/28/2020 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological), LENVIMA | Food and Beverage | In-kind items and services | $18.57 | General |
| Category: ONCOLOGY | ||||||
| 01/17/2020 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $13.85 | General |
| Category: Oncology | ||||||
| 01/09/2020 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $22.52 | General |
| Category: Anemia | ||||||
| 12/17/2019 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $23.37 | General |
| 12/16/2019 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $15.94 | General |
| Category: ONCOLOGY | ||||||
| 12/12/2019 | GENZYME CORPORATION | JEVTANA (Drug) | Food and Beverage | In-kind items and services | $22.46 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2019 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $12.50 | General |
| Category: ONCOLOGY | ||||||
| 12/02/2019 | AbbVie, Inc. | Venclexta (Drug) | Food and Beverage | In-kind items and services | $20.67 | General |
| Category: Virology | ||||||
| 11/19/2019 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological), LENVIMA | Food and Beverage | In-kind items and services | $8.38 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2019 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $11.79 | General |
| 11/04/2019 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $15.89 | General |
| Category: Anemia | ||||||
| 10/29/2019 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $12.27 | General |
| Category: ONCOLOGY | ||||||
| 10/28/2019 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $21.58 | General |
| 10/24/2019 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $10.53 | General |
| Category: ONCOLOGY | ||||||
| 10/17/2019 | Exelixis Inc. | Cabometyx (Drug) | Food and Beverage | In-kind items and services | $19.60 | General |
| Category: Oncology | ||||||
| 10/08/2019 | Genentech USA, Inc. | Rituxan (Biological), Actemra | Food and Beverage | In-kind items and services | $14.47 | General |
| Category: BioOncology/Immunology | ||||||
| 10/07/2019 | AbbVie, Inc. | Venclexta (Drug) | Education | In-kind items and services | $99.00 | General |
| Category: Virology | ||||||
| 10/07/2019 | AbbVie, Inc. | Venclexta (Drug) | Food and Beverage | In-kind items and services | $24.17 | General |
| Category: Virology | ||||||
| 09/17/2019 | E.R. Squibb & Sons, L.L.C. | EMPLICITI (Biological) | Food and Beverage | Cash or cash equivalent | $18.92 | General |
| Category: Oncology | ||||||
| 09/17/2019 | E.R. Squibb & Sons, L.L.C. | EMPLICITI (Biological) | Food and Beverage | Cash or cash equivalent | $0.73 | General |
| Category: Oncology | ||||||
| 09/12/2019 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $24.54 | General |
| Category: Anemia | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 56 | 2,538 | 36,428 | $790,492 | $226,505 |
| 2022 | 47 | 2,331 | 22,403 | $509,468 | $159,866 |
| 2021 | 5 | 243 | 291 | $89,027 | $29,460 |
| 2020 | 1 | 49 | 50 | $11,600 | $2,356 |
Total Patients
5,161
Total Services
59,172
Medicare Billing
$418,187
Procedure Codes
112
All Medicare Procedures & Services
112 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 15 | 2,760 | $152,972 | $50,699 | 33.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 194 | 350 | $118,679 | $32,408 | 27.3% |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | Office | 2023 | 11 | 264 | $130,800 | $25,666 | 19.6% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 24 | 20,250 | $49,710 | $17,770 | 35.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 82 | 111 | $51,228 | $14,601 | 28.5% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 55 | 114 | $38,708 | $10,718 | 27.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 52 | 52 | $22,525 | $6,163 | 27.4% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 259 | 567 | $22,172 | $5,861 | 26.4% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 15 | 3,770 | $12,818 | $5,174 | 40.4% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 281 | 674 | $20,081 | $5,119 | 25.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 32 | 32 | $14,310 | $4,194 | 29.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 234 | 497 | $5,063 | $4,160 | 82.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 23 | 38 | $11,455 | $3,417 | 29.8% |
| 84238 | Chemical receptor analysis | Office | 2023 | 58 | 90 | $11,436 | $3,226 | 28.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 32 | 48 | $8,797 | $2,868 | 32.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 43 | 46 | $10,476 | $2,567 | 24.5% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 49 | 211 | $7,722 | $2,421 | 31.4% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 43 | 52 | $7,926 | $2,377 | 30.0% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 13 | 44 | $7,772 | $2,361 | 30.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 12 | 12 | $6,894 | $1,976 | 28.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 17 | 17 | $5,316 | $1,664 | 31.3% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 25 | 43 | $4,899 | $1,596 | 32.6% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 21 | 33 | $4,949 | $1,566 | 31.6% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 73 | 115 | $4,910 | $1,518 | 30.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 73 | 119 | $4,571 | $1,214 | 26.6% |
About Dr. Matthew Shupe, D.O
Dr. Matthew Shupe, D.O is a Hematology & Oncology healthcare provider based in Lincoln, Nebraska. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/27/2009. The National Provider Identifier (NPI) number assigned to this provider is 1629206750.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Matthew Shupe, D.O has received a total of $4,207 in payments from pharmaceutical and medical device companies, with $221.66 received in 2024. These payments were reported across 230 transactions from 41 companies. The most common payment nature is "Food and Beverage" ($3,765).
As a Medicare-enrolled provider, Shupe has provided services to 5,161 Medicare beneficiaries, totaling 59,172 services with total Medicare billing of $418,187. Data is available for 4 years (2020–2023), covering 112 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Lincoln, NE
- Active Since 06/27/2009
- Last Updated 12/31/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1629206750
Products in Payments
- KEYTRUDA (Biological) $544.82
- Venclexta (Drug) $224.61
- OPDIVO (Biological) $220.63
- Cabometyx (Drug) $215.55
- INJECTAFER (Drug) $144.75
- SOLIRIS (Drug) $132.87
- TUKYSA (Drug) $111.11
- JEVTANA (Drug) $107.92
- IMFINZI (Drug) $93.00
- GILOTRIF (Drug) $92.11
- Lenvima (Drug) $89.51
- IBRANCE (Drug) $82.65
- Revlimid (Drug) $80.90
- ADCETRIS (Biological) $72.98
- Rubraca (Drug) $66.45
- XPOVIO (Drug) $62.02
- Kyprolis (Biological) $53.01
- Zelboraf (Drug) $48.72
- EPKINLY (Drug) $47.87
- FERAHEME (Drug) $47.18
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Lincoln
Mr. Steven Dunder, Md, MD
Hematology & Oncology — Payments: $26,199
Hematology & Oncology $26,199
Nathan Green, Do, DO
Hematology & Oncology — Payments: $10,159
Hematology & Oncology $10,159
Wallace Peterson, Md, MD
Hematology & Oncology — Payments: $6,017
Hematology & Oncology $6,017
Melissa Cetak, Aprn, APRN
Hematology & Oncology — Payments: $5,017
Hematology & Oncology $5,017
Dr. Joni Tilford, Md, MD
Hematology & Oncology — Payments: $4,721
Hematology & Oncology $4,721
Kathleen Tonkin, Pac, PAC
Hematology & Oncology — Payments: $3,117
Hematology & Oncology $3,117